



BAFNA PHARMACEUTICALS LTD.,

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE:+044-25267517/25270992, FAX:91-44-25231264, Email: info@bafnapharma.com, website: www.bafnapharma.com

Ref: BPL/ 745 / 12-13

09.02.2013

Listing Department
The Bombay Stock Exchange Limited
P J Towers
Dalal Street
Mumbai – 400 001
SCRIP CODE: 532989

Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E)
Mumbai – 400051
SCRIP SYMBOL: BAFNAPHARM

ISIN: INE 878I01014

Dear Sir

Sub: Outcome of the Board meeting held on 09.02.2013 – Reg.

We wish to inform you that, among the others following is the outcome of the meeting of the Board of Directors of the company held on Saturday the 9th day of February, 2013:

Approved the unaudited quarterly results for the quarter ending 31st December, 2012

Also find enclosed the Limited Review Report for the quarter ended 31st December, 2012 as per Clause 41 of the Listing Agreement.

These are for your kind information & records and treat this as compliance with Listing Agreement.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully
For BAFNA PHARMACEUTICALS LIMITED


Bafna Mahaveer Chand
Managing Director



Encl: As above.

BAFNA PHARMACEUTICALS LIMITED


Regd office: 299, THAMBU CHETTY STREET, CHENNAI- 600 001

Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months Ended 31st December 2012

PART I

(Rs. In lakhs)

Particulars	3 months ended (31-12-2012)	Preceding 3 months ended (30-09- 2012)	Corresponding 3 months ended (31-12-2011) in the previous year	STANDALONE		
				Year to date figures for the current period ended	Year to date figures for the Previous year ended	Previous year ended
				(31-12-2012)	(31-12-2011)	(31-03-2012)
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Income form Operations						
(a) Net Sales/Income from Operations (net of excise duty)	2,599.09	5,636.81	2,106.94	11,647.44	8,824.57	12,098.20
(b) Other Operating Income	179.44	182.44	-	385.39		-
Total income from operations (net)	2,778.54	5,819.25	2,106.94	12,032.83	8,824.57	12,098.20
2. Expenditure	-					
a. Cost of materials consumed	1,125.25	936.40	1,273.40	3,245.63	6,739.80	3,651.62
b. Purchase of stock-in-trade	958.55	3,682.05	-	5,849.20	-	6,335.93
c. Changes in inventories of finished goods, WIP and stock-in-trade	(515.68)	171.54	(56.20)	(378.11)	(270.48)	(581.83)
d. Employees benefits expense	348.01	225.11	159.29	780.10	482.35	566.70
e. Depreciation and amortisation expense	202.44	159.87	297.56	538.88	483.22	583.80
f. Other expenditure (Any item exceeding 10% of the total expenses relating to continuing operations)	258.43	196.34	186.53	702.66	459.75	581.71
Total Expenses	2,377.00	5,371.30	1,860.59	10,738.35	7,894.64	11,137.94
3. Profit/(Loss) from Operations before Other Income, finance cost and Exceptional Items (1-2)	401.54	447.95	246.36	1,294.47	929.93	960.26
4. Other Income	51.72	60.74	61.46	143.42	113.12	402.62
5. Profit/(Loss) from ordinary activities before finance cost and Exceptional Items (3+/- 4)	453.26	508.69	307.82	1,437.89	1,043.05	1,362.88
6. Finance Costs	277.78	255.24	183.44	795.99	518.43	813.24
7. Profit/(Loss) from ordinary activities after finance cost but before Exceptional Items (5+/- 6)	175.48	253.45	124.38	641.90	524.63	549.65
8. Exceptional items	-	-		-	37.70	13.11
9. Profit / Loss from Ordinary Activities before tax (7+/- 8)	175.48	253.45	124.38	641.90	486.92	536.53
10. Tax expense	34.63	46.60	(52.59)	188.09	70.64	329.13
11. Net Profit / Loss from Ordinary Activities after tax (9 +/- 10)	140.85	206.85	176.97	453.81	416.28	207.41
12. Extraordinary Item (net of tax expense Rs. _____ lacs)	-	-		-		-
13. Net Profit/ Loss for the period (11 +/- 12)	140.85	206.85	176.97	453.81	416.28	207.41
14. Share of profit/ (loss) of associates*		-		-	-	-
15. Minority Interest*		-		-	-	-
16. Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 +/- 14 +/- 15)*		-	-	-	-	-
17. Paid up equity share capital (Face value of Rs.10/- each)	1,865.63	1,865.63	1,748.13	1,865.63	1,748.13	1,838.13
18. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting		-				
19 (i). Earnings Per Share (EPS) (before extraordinary items) (not annualised)						
a) Basic	0.75	1.11	1.01	2.43	2.38	1.19
b) Diluted	0.75	1.11	1.01	2.43	2.38	1.19
19 (ii). Earning per share (after extraordinary items) (not annualised)						
a) Basic	0.75	1.11	1.01	2.43	2.38	1.19
b) Diluted	0.75	1.11	1.01	2.43	2.38	1.19



PART II

Particulars	3 months ended (31.12.2012)	Preceding 3 months ended (30.09.2012)	Corresponding 3 months ended in the previous year 31-12-2011	Year to Date figures for current Period ended (31-12-2012)	Year to date figures for the Previous year ended (31-12-2011)	Previous year ended (31-03-2012)
	Unaudited	Unaudited	Unaudited	Unaudited		Audited
A. Particulars of Shareholding						
1.Public Shareholding						
- No. of shares	11,559,886	11,080,313	10,300,053	11,559,886	10,300,053	10,980,795
- Percentage of shareholding	61.96	59.39	58.92	61.96	58.92	59.74
2. Promoters and promoter group shareholding**						
a) Pledged/Encumbered						
- Number of shares	1,283,000	1,003,000	1,728,000	1,283,000	1,728,000	1,003,000
- Percentage of shares (as a% of the total shareholding of promoter and promoter group)	18.08	13.24	24.06	18.08	24.06	13.65
- Percentage of shares (as a% of the total share capital of the Company)	6.88	5.38	9.88	6.88	9.88	5.46
b) Non-encumbered						
- Number of Shares	5,813,449	6,573,022	5,453,282	5,813,449	5,453,282	6,397,540
- Percentage of shares (as a% of the total shareholding of promoter and promoter group)	81.92	86.76	75.94	81.92	75.94	86.45
- Percentage of shares (as a % of the total share capital of the company)	31.16	35.23	31.20	31.16	31.20	34.80

1. The above unaudited quarterly financial results were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their Meeting held on 09.02.2013

2. Status of Investor Complaints.:

Opening balance	Nil
Pending at the beginning of the quarter	Nil
No. of complaints received and disposed off during the quarter	Nil
Complaints pending at the end of the quarter	Nil

3. The Company operates only in one segment, ie. Pharmaceutical formulations, as such reporting is done on a single segment basis.

4. The figures for the previous periods have been regrouped wherever necessary .

5. The Limited Review as required under Clause 41 of the Listing Agreement has been completed by the statutory Auditors for the Quarter ended 31.12.2012

6. The MD, CEO and Manager-Accounts & Finance certificate in respect of the above results in terms of the requirement of Clause 41 of the Listing Agreement has been placed before the Board of Directors.

For BAFNA PHARMACEUTICALS LIMITED

(BAFNA MAHAVEER CHAND)
Managing Director

Place: Chennai

Date: 09.02.2013